AR090738A1 - Metodos para el tratamiento de espondilitis anquilosante usando antagonistas de il-17 - Google Patents

Metodos para el tratamiento de espondilitis anquilosante usando antagonistas de il-17

Info

Publication number
AR090738A1
AR090738A1 ARP130101282A AR090738A1 AR 090738 A1 AR090738 A1 AR 090738A1 AR P130101282 A ARP130101282 A AR P130101282A AR 090738 A1 AR090738 A1 AR 090738A1
Authority
AR
Argentina
Prior art keywords
treatment
methods
patient
ankylosing spondylitis
antagonist
Prior art date
Application number
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR090738A1 publication Critical patent/AR090738A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se refiere a terapias personalizadas y a los métodos para el tratamiento de espondilitis anquilosante (AS). De una manera específica, esta descripción se refiere a métodos para el tratamiento de un paciente que tenga espondilitis anquilosante (AS) mediante la administración selectiva de un antagonista de IL-17 (interleuquina-17), por ejemplo, un anticuerpo para IL-17, tal como secukinumab, al paciente con espondilitis anquilosante (AS) con base en que ese paciente tenga predisposición para tener una respuesta favorable al tratamiento con el antagonista de IL-17. También en la presente se dan a conocer métodos de diagnóstico y formas transmisibles de información útiles para predecir la probabilidad de que un paciente que tenga espondilitis anquilosante (AS) responderá al tratamiento con un antagonista de IL-17, por ejemplo, con un anticuerpo para IL-17, tal como secukinumab.
ARP130101282 2012-04-20 2013-04-18 Metodos para el tratamiento de espondilitis anquilosante usando antagonistas de il-17 AR090738A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261636062P 2012-04-20 2012-04-20

Publications (1)

Publication Number Publication Date
AR090738A1 true AR090738A1 (es) 2014-12-03

Family

ID=48325883

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101282 AR090738A1 (es) 2012-04-20 2013-04-18 Metodos para el tratamiento de espondilitis anquilosante usando antagonistas de il-17

Country Status (13)

Country Link
US (1) US20150125462A1 (es)
EP (1) EP2838560A2 (es)
JP (1) JP2015519311A (es)
KR (1) KR20150010709A (es)
CN (1) CN104244979A (es)
AR (1) AR090738A1 (es)
AU (1) AU2013249232A1 (es)
BR (1) BR112014025768A2 (es)
CA (1) CA2870025A1 (es)
MX (1) MX2014012640A (es)
RU (1) RU2014146594A (es)
TW (1) TW201347771A (es)
WO (1) WO2013158821A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014155278A2 (en) * 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
EP3365011A1 (en) * 2015-10-19 2018-08-29 Novartis AG Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
CN116059350A (zh) 2015-10-27 2023-05-05 Ucb生物制药有限责任公司 使用抗-il-17a/f抗体的治疗方法
AU2018361975A1 (en) * 2017-11-02 2020-05-07 Novartis Ag Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
US11894121B2 (en) 2021-08-06 2024-02-06 Reviv Global Ltd Prescriptive nutrition-based IV and IM infusion treatment formula creation systems and methods
US11600375B2 (en) 2021-07-30 2023-03-07 Reviv Global Ltd Genetically personalized food recommendation systems and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PT1963368E (pt) 2005-12-13 2012-09-14 Lilly Co Eli Anticorpos anti-il-17
JP5068270B2 (ja) 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
WO2010034443A1 (en) 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Antibodies against human il 17 and uses thereof

Also Published As

Publication number Publication date
WO2013158821A2 (en) 2013-10-24
WO2013158821A3 (en) 2014-03-13
BR112014025768A2 (pt) 2017-07-04
RU2014146594A (ru) 2016-06-10
CN104244979A (zh) 2014-12-24
US20150125462A1 (en) 2015-05-07
JP2015519311A (ja) 2015-07-09
MX2014012640A (es) 2015-01-15
EP2838560A2 (en) 2015-02-25
KR20150010709A (ko) 2015-01-28
AU2013249232A1 (en) 2014-10-09
CA2870025A1 (en) 2013-10-24
TW201347771A (zh) 2013-12-01

Similar Documents

Publication Publication Date Title
AR090738A1 (es) Metodos para el tratamiento de espondilitis anquilosante usando antagonistas de il-17
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
DOP2015000261A (es) Compuesto peptídico como activador de los receptores del glp-1 y del gip
SV2018005678A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
GT201700033A (es) Anticuerpos anti tigit
ECSP17001673A (es) Anticuerpos monoclonales contra el epitope de her2
CL2016002816A1 (es) Anticuerpos anti-cd 134 (ox40) y usos de los mismos (divisional de sol. n° 631-14).
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
CY1121335T1 (el) Anti-cxcr3 αντισωματα
ES2653487T3 (es) Receptor de antígeno quimérico y métodos de uso del mismo
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
ECSP12012221A (es) Anticuerpos anti-cd40
NZ723858A (en) Anti-human ox40l antibodies, uses & methods
EA201291133A1 (ru) Антитела, обладающие пониженной иммуногенностью в организме человека
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
TWD164979S (zh) 汽車用水箱護罩
BR112017015880A2 (pt) anticorpos, usos e métodos
BR112017011576A2 (pt) película elástica com aberturas não tecida com características de ligação melhoradas
UY35463A (es) Formulaciones de polipéptido fc-factor ix.
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
MX2016003674A (es) Matrices detectables, sistemas para el diagnostico y sus metodos de preparacion y uso.
BR112019004715A2 (pt) métodos para detectar anticorpos neutralizantes anti-leptina
MX2020003667A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona.
BR112015022953A2 (pt) receptores pyr/pyl modificados ativados por ligantes ortogonais
CL2015003554A1 (es) Preparado farmacéutico.

Legal Events

Date Code Title Description
FB Suspension of granting procedure